Actively Recruiting
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
Led by Shenzhen Geno-Immune Medical Institute · Updated on 2025-09-08
100
Participants Needed
4
Research Sites
230 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19) and CD20 (4SCAR20), CD22 (4SCAR22), CD30 (4SCAR30), CD38 (4SCAR38), CD70 (4SCAR70) or CD123 (4SCAR123) for patients with B cell malignancies. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.
CONDITIONS
Official Title
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age older than 6 months
- Malignant B cell surface expression of CD19, CD20, CD22, CD30, CD38, CD70, or CD123 molecules
- Karnofsky Performance Score over 80 points and expected survival time more than 1 month
- Hemoglobin level greater than 80 g/L
- No contraindications to blood cell collection
You will not qualify if you...
- Presence of other active diseases making treatment response difficult to assess
- Uncontrolled bacterial, fungal, or viral infection
- Living with HIV
- Active hepatitis B or hepatitis C infection
- Pregnant or nursing mothers
- Systemic steroid treatment within one week before treatment
- Prior failed CAR-T treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China, 510282
Actively Recruiting
2
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China, 510282
Actively Recruiting
3
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, China, 518000
Actively Recruiting
4
Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center
Kunming, Yunnan, China, 650000
Actively Recruiting
Research Team
L
Lung-Ji Chang, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here